This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
But not everyone in drugdevelopment is playing this game. No wonder investing in drugdevelopment is so hard! The single most important skill for investing in drugdevelopment, or managing a portfolio of assets in a company, is recognizing when the “switch point” comes for each asset.
It is hard to ignore some of the most pressing, long-term trends driving the push to accelerate innovation and progress in drugdevelopment. As a result, biopharma and biotech companies working to bring their drug pipelines to the market require deep expertise from trusted partners to help deliver critical therapies for their patients.
This shift has led to the emergence of integrated contract development and manufacturing organizations (CDMOs), which provide end-to-end support for drugdevelopers. Reshaping drugdevelopment through CRO/CDMO integration. Integrated CDMO and CRO Services Creates Innovation in Early-Stage DrugDevelopment.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management.
Given macro healthcare influences (eg, economic uncertainty, environmental changes) and the numerous available treatments for major diseases, drugdevelopers may need to reassess their therapeutic strategies. This has led drugdevelopers to unintentionally limit their potential within chosen therapeutic spaces.
How can these increase the probability of success or efficiency in a pre-clinical and clinical drugdevelopment program? Regulatory agencies have set the framework and use cases for RWE.
The pharmaceutical industry, particularly the generic drug sector, faces significant challenges in adopting sustainable practices. This article outlines key considerations and strategies for developing a sustainable generic drugdevelopment strategy. “Generics are known for their cost-effectiveness.
The review provides a comprehensive analysis of non-hydroxamate inhibitors for IspC, an enzyme crucial in the MEP pathway, highlighting its structural diversity and improved drugdevelopment potential.
These methods have the potential to revolutionize the drug discovery process by enhancing the efficiency and accuracy of identifying and developing new drug candidates. This article will explore how machine learning can be leveraged to optimize generic drugdevelopment… Source
"Unlock Hidden Profits in Pharmaceutical R&D: A recent analysis of top-selling medications reveals that companies that closely monitor their competitors' patent portfolios are 3x more likely to achieve a higher return on investment in drugdevelopment. link] #pharmaceuticalinnovation #drugdevelopment #patentportfolio"
Molecular docking and in vitro assays confirm improved binding affinity and cytotoxicity, highlighting CA4's potential as a promising drug candidate for cancer therapy. ABSTRACT The development of novel therapeutic drugs with enhanced efficacy has gained significant attention in recent years.
Generic drugs play a crucial role in providing affordable healthcare options to millions of patients worldwide. One of the key tools that generic drug manufacturers rely on to navigate the complex regulatory environment is the FDA’s Product Specific Guidances (PSGs).
Patient centricity has become a crucial aspect of the pharmaceutical industry, particularly in the development of generic drugs. Here, we will explore the best practices in patient centricity for generic drugdevelopment… Source
The biotech is telling investors it expects to launch as many as 15 new products in five years, a bold goal that will require a lot to go right to pull off.
Breaking Down Barriers: The Power of Global Research Collaborations in Generic DrugDevelopment As the world grapples with the complexities of healthcare, one thing is clear: the need for innovative solutions has never been more pressing. The benefits of international collaborations in generic drugdevelopment are multifaceted.
As the pharmaceutical industry continues to evolve, drugdevelopers encounter new challenges and opportunities in their pursuit of innovation. In response, the PPD clinical research business of Thermo Fisher Scientific conducted its third global survey of 150 drugdevelopers to capture a comprehensive view of these evolving trends.
Accelerating Generic DrugDevelopment: Strategies for Success As a pharmaceutical professional, you know how crucial it is to navigate the complex landscape of generic drugdevelopment. The generic drugdevelopment process involves several stages, from patent research to regulatory approvals.
The Unsung Heroes of Generic DrugDevelopment: The Power of Partnerships As we navigate the complex landscape of pharmaceuticals, it's easy to overlook the crucial role that partnerships play in bringing affordable, life-saving medications to market. When it comes to developing generic drugs, partnerships can take many forms.
Revolutionizing Generic DrugDevelopment: The Power of Digital Transformation As the pharmaceutical industry continues to evolve, one thing is clear: digital transformation is no longer a luxury, but a necessity. For years, generic drug manufacturers have relied on traditional methods to develop and launch new products.
This growth is driven by several factors, including the increasing prevalence of chronic diseases, cost-effectiveness, and patent expirations of branded drugs. The future of generic drugdevelopment in emerging markets looks promising, with technological advancements… Source
The regulatory environment in Japan for generic drugdevelopment is complex and has undergone significant changes in recent years. Regulatory Authority: Pharmaceuticals and Medical Devices Agency (PMDA) The PMDA is the primary regulatory authority responsible for overseeing the drug approval process in Japan.
Leveraging Machine Learning to Accelerate DrugDevelopment Discover how CDMOs are using machine learning to speed up drugdevelopment, cut costs, and improve quality. mcottam Mon, 06/23/2025 - 14:54 Discover how CDMOs are using machine learning to speed up drugdevelopment, cut costs, and improve quality.
The funding, which is part of ACT for ALS, will support expanded access studies of drugsdeveloped by Prilenia Therapeutics, Clene Nanomedicine and Rapa Therapeutics.
The pharmaceutical industry is undergoing significant transformations, particularly in the realm of generic drugdevelopment. Recent trends and advancements in technology, research, and collaboration are reshaping the landscape of generic drugdevelopment, leading to new opportunities and challenges for pharmaceutical companies.
"Compliance in Generic DrugDevelopment: A Critical Component of Success As the generic drug industry continues to grow, ensuring compliance with regulatory requirements has become a top priority for pharmaceutical companies.
The deal adds to recent M&A activity as well as signals pharma’s continued interest in pills for inflammatory conditions, which are meant to approach the potency of injectable therapies.
Neumora’s filing late Friday, along with that of radiopharmaceutical startup RayzeBio earlier this week, could be an important test of the biotech IPO market.
The funding for Rapport Therapeutics saw participation from a series of so-called crossover investors, many of which have pulled back from biotech startups in recent years.
Regulatory Guidance for Oligonucleotide Bioanalysis in DrugDevelopment pmjackson Wed, 02/19/2025 - 21:30 The unique physicochemical properties of oligonucleotides require the use of specialized bioanalytical approaches, with key considerations including selectivity and specificity, sensitivity, stability, and matrix effects.
The brain drugdeveloper is letting go of around 41 of its 238 employees, in a move the company says will help “align resources” with its strategic priorities.
The Generic Drug Revolution: Setting the Stage Before we dive into the nitty-gritty, let’s take a moment to appreciate the impact of generic drugs. Did you know that generic drugs now make up about 90% of all prescription drug purchases in the United States, while accounting for only 20% of prescription drug spending[1]?
Choosing the right clinical outcome assessments (COAs) is an important part of successfully advancing drugdevelopment and securing regulatory approval.
The Unseen Heroes of Generic DrugDevelopment: Pharmacovigilance As a generic drugdeveloper, you're no stranger to the challenges of bringing affordable medications to market. But have you ever stopped to think about the unsung heroes of generic drugdevelopment?
The proposed takeout follows a spate of dealmaking around antibody-drug conjugates, targeted cancer medicines that have lured AbbVie, Pfizer, Merck and Gilead.
Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drugdevelopment has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drugdevelopment.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content